Tisagenlecleucel, sold under the brand name Kymriah was the first gene therapy approved by the FDA on 30 August 2017....
On August 11, 2022, the FDA gave the green light for accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) to treat adult...
On August 10, 2022, the Food and Drug Administration granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic...
New hope for myelofibrosis patients was announced in August 2022, after the acceptance of the new drug application (NDA) for...
Today represents a key milestone for beta-thalassemia patients battling hereditary chronic disease. This comes after the approval that was granted...
During the last three months, the FDA approved several molecules and indications. In May, the following indications were approved: Fam-trastuzumab...
Voxelotor (Oxbryta) is the first hemoglobin oxygen-affinity modulator. It has disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators...
On June 18, 2020, the Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK), the first-in-class EZH2 inhibitor. The...
Ipsen announced that it entered into a definitive merger agreement to acquire Epizyme. The acquisition is anticipated to be closed...
Pfizer has agreed to acquire Global Blood Therapeutics for $5.4 billion. Based on this, Global Blood Therapeutics will hand its...
